Table 4.

Univariate and multivariate Cox regression analysis for overall survival (OS) in NSCLC patients (N = 125).

	Univariate Analysis
Cox Regression	HR (95% CI)	p Value
Age (<65 vs. ≥65)	1.214 (0.846–1.742)	0.292
Gender (male vs. female)	1.546 (0.933–2.622)	0.090
ECOG PS (≥2 vs. 0–1)	2.289 (1.353–3.871)	0.002 *
Stage at Diagnosis (IV vs. <IV)	1.542 (0.627–3.793)	0.346
Histology (SqCC vs. non-SqCC)	1.262 (0.850–1.874)	0.249
No. of Metastatic Sites (≥3 vs. 0–2)	1.589 (1.028–2.456)	0.037 *
Brain Metastases (yes vs. no)	1.082 (0.653–1.793)	0.759
Liver Metastases (yes vs. no)	1.826 (1.190–2.802)	0.006 *
Bone Metastases (yes vs. no)	1.416 (0.965–2.078)	0.075
let-7c (high vs. low)	1.050 (0.724–1.524)	0.797
miR-26a (high vs. low)	1.329 (0.907–1.946)	0.145
miR-30d (high vs. low)	1.251 (0.865–1.809)	0.235
miR-98 (high vs. low)	1.101 (0.725–1.673)	0.651
miR-195 (high vs. low)	1.307 (0.894–1.911)	0.167
miR-202 (high vs. low)	1.596 (1.074–2.292)	0.020 *
Multivariate Analysis
Cox Regression	HR (95% CI)	p Value
ECOG PS (≥2 vs. 0–1)	2.065 (1.215–3.581)	0.008 *
No. of Metastatic Sites (≥3 vs. 0–2)	1.230 (0.751–2.016)	0.410
Liver Metastases (yes vs. no)	1.666 (1.033–2.687)	0.036 *
miR-202 (high vs. low)	1.558 (1.060–2.291)	0.024 *

HR, hazard ratio; CI, confidence intervals; ECOG PS, Eastern Cooperative Oncology Group Performance Status; patients were classified into high and low expression groups according to the median value of each miRNA; Cox regression, * p < 0.05.